Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

“…However, after three months, antibody waning accounted for 41.7%, 36.6%, and 30.9% of loss for AZ, BNT, and m1730, respectively [39] . However still higher than homologous BBIBBP boosting observed in naive COVID-19 population [36] .…”

“…Previous reports show that application site reaction was the most frequent event [17] , [22] , [44] . However, BBIBP and CV homologous boosters reported fewer local and systemic adverse events than inactivated virus/mRNA heterologous boosters [36] , [55] . In two-dose BBIBP subjects, the pain site reported was similar across BNT, m1730, and Chad boosted (90-94%).…”

“…Heterologous boosting regimes provide stronger and more sustained immune responses for mRNA and adenoviral vector vaccines [20] , [21] , similarly occurring among heterologous viral inactivated vaccine boosters, as reported for CV and BBIBP [33] , [34] , [35] , [36] , [37] . However, most studies are focused on the effect of boosting mRNA and adenoviral vector vaccines [20] , [21] .…”

Long‐term immunogenicity and safety of heterologous boosting with a SARS‐CoV‐2 mRNA vaccine (SYS6006) in Chinese participants who had received two or three doses of inactivated vaccine

“…The AE incidence observed in this study was comparable or lower than those observed with other mRNA vaccines when given as heterologous booster dose. 10,20,21 It is noteworthy that fever was defined as axillary temperature ≥37.3°C in our study per the official guideline, but defined as oral temperature ≥38.0°C in other studies. 10,20,21 Notably, most of the AEs were mild or moderate in intensity.…”

“…10,20,21 It is noteworthy that fever was defined as axillary temperature ≥37.3°C in our study per the official guideline, but defined as oral temperature ≥38.0°C in other studies. 10,20,21 Notably, most of the AEs were mild or moderate in intensity. The AEs incidence and intensity were similar between the two groups of participants who had received two or three doses of inactivated vaccine previously.…”